Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy

Journal of the American Society of Nephrology

Volumn 27, Issue 5, 2016, Pages 1517-1533

  Seitz Polski, Barbara ^a,b   Dolla, Guillaume ^a   Payré, Christine ^a   Girard, Christophe A ^a   Polidori, Joel ^a   Zorzi, Kevin ^b   Birgy Barelli, Eléonore ^a   Jullien, Perrine ^c   Courivaud, Cécile ^d   Krummel, Thierry ^e   Benzaken, Sylvia ^b   Bernard, Ghislaine ^b   Burtey, Stéphane ^f   Mariat, Christophe ^d   Esnault, Vincent L M ^b   Lambeau, Gérard ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c UNIVERSITÉ JEAN MONNET   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^f HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY; BIOLOGICAL MARKER; C TYPE LECTIN DOMAIN 1 ANTIGEN; C TYPE LECTIN DOMAIN 7 ANTIGEN; CREATININE; CYCLOSPORIN; CYSTEINE RICH ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPITOPE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPASE A2 RECEPTOR; PHOSPHOLIPASE A2 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ANALYTICAL PARAMETERS; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DELETION MUTANT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DIURETIC THERAPY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INDEPENDENT VARIABLE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; NEPHROTIC SYNDROME; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; PROTEINURIA; REMISSION; RISK FACTOR; SURVIVAL ANALYSIS; SURVIVAL RATE; URINARY PROTEIN CREATININE RATIO; IMMUNOLOGY;

AUTOANTIBODIES; EPITOPES; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, PHOSPHOLIPASE A2;

EID: 85015131433     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014111061     Document Type: Article

References (38)

1. Ponticelli C, Glassock RJ: Treatment of membranous nephropathy in patients with renal insufficiency: what regimen to choose? J Nephrol 26: 427-429, 2013
2. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
3. Qin W, Beck LH Jr, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z: Antiphospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 22: 1137-1143, 2011
4. Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ: Antiphospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 6: 1286-1291, 2011
5. Oh YJ, Yang SH, Kim DK, Kang SW, Kim YS: Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS One 8: e62151, 2013
6. Akiyama S, Akiyama M, Imai E, Ozaki T, Matsuo S, Maruyama S: Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol 19: 653-660, 2015
7. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG,Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ: Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 22: 1543-1550, 2011
8. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R,Mathieson PW, Ronco P, Brenchley PE, Wetzels JF: Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1735-1743, 2012
9. Ruggenenti P, Debiec H, Ruggiero B, Chianca A, Pellé T, Gaspari F, Suardi F, Gagliardini E, Orisio S, Benigni A, Ronco P, Remuzzi G: Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy [published online ahead of printMarch 24, 2015], J AmSoc Nephrol doi: 10.1681/ASN.2014070640
10. Seitz-Polski B, Payré C, Ambrosetti D, Albano L, Cassuto-Viguier E, Berguignat M, Jeribi A, ThouretMC, Bernard G, Benzaken S, Lambeau G, Esnault VL: Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients. Nephrol Dial Transplant 29: 2334-2342, 2014
11. Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, NikamM, Poulton K,McWilliam L, Short CD, Venning M, Brenchley PE: Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83: 940-948, 2013
12. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA: Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 25: 1357-1366, 2014
13. Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P: Rituximab for idiopathic membranous nephropathy. Lancet 360: 923-924, 2002
14. Hofstra JM, Fervenza FC, Wetzels JF: Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 9: 443-458, 2013
15. Radhakrishnan J, Cattran DC: The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines-application to the individual patient. Kidney Int 82: 840-856, 2012
16. Ancian P, Lambeau G, Mattéi MG, Lazdunski M: The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J Biol Chem 270: 8963-8970, 1995
17. Beck LH Jr: The dominant humoral epitope in phospholipase A2 receptor-1: presentation matters when serving up a slice of p. J Am Soc Nephrol 26: 237-239, 2015
18. Kao L, Lam V, Waldman M, Glassock RJ, Zhu Q: Identification of the immunodominant epitope region in phospholipase A2 receptormediating autoantibody binding in idiopathic membranous nephropathy. J Am Soc Nephrol 26: 291-301, 2015
19. Fresquet M, Jowitt TA, Gummadova J, Collins R, O'Cualain R, McKenzie EA, Lennon R, Brenchley PE: Identification of amajor epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol 26: 302-313, 2015
20. Haas M: IgG subclass deposits in glomeruli of lupus and nonlupus membranous nephropathies. Am J Kidney Dis 23: 358-364, 1994
21. Huang CC, Lehman A, Albawardi A, Satoskar A, Brodsky S, Nadasdy G, Hebert L, Rovin B, Nadasdy T: IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression. Mod Pathol 26: 799-805, 2013
22. Stanescu HC, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L, Voinescu C, Patel N, Pearce K, Hubank M, Stephens HA, Laundy V, Padmanabhan S, Zawadzka A, Hofstra JM, Coenen MJ, den Heijer M, Kiemeney LA, Bacq-Daian D, Stengel B, Powis SH, Brenchley P, Feehally J, Rees AJ, Debiec H, Wetzels JF, Ronco P, Mathieson PW, Kleta R: Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 364: 616-626, 2011
23. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85-89, 1993
24. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E: Validation of a predictivemodel of idiopathicmembranous nephropathy: its clinical and research implications. Kidney Int 51: 901-907, 1997
25. CoenenMJ, Hofstra JM, Debiec H, Stanescu HC,Medlar AJ, Stengel B, Boland-Augé A, Groothuismink JM, Bockenhauer D, Powis SH, Mathieson PW, Brenchley PE, Kleta R, Wetzels JF, Ronco P: Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy. J Am Soc Nephrol 24: 677-683, 2013
26. Chen JL, Hu SY, Jia XY, Zhao J, Yang R, Cui Z, Zhao MH: Association of epitope spreading of antiglomerular basement membrane antibodies and kidney injury. Clin J Am Soc Nephrol 8: 51-58, 2013
27. LiN, Aoki V, Hans-FilhoG, Rivitti EA, Diaz LA: The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J Exp Med 197: 1501-1510, 2003
28. van derWoude D, AlemayehuWG, VerduijnW, de Vries RR, Houwing-Duistermaat JJ, Huizinga TW, Toes RE: Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis. Nat Genet 42: 814-816, author reply 816, 2010
29. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD: Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med 182: 75-85, 1995
30. Goebels, N, Hofstetter, H, Schmidt, S, Brunner, C, Wekerle, H, Hohlfeld, R: Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain: a journal of neurology, 123 Pt 3: 508-518, 2000.
31. Naserke HE, Ziegler AG, Lampasona V, Bonifacio E: Early development and spreading of autoantibodies to epitopes of IA-2 and their association with progression to type 1 diabetes. J Immunol 161: 6963-6969, 1998
32. Shah P, Tramontano A,Makker SP: Intramolecular epitope spreading in Heymann nephritis. J Am Soc Nephrol 18: 3060-3066, 2007
33. Karandikar NJ, Eagar TN, Vanderlugt CL, Bluestone JA, Miller SD: CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 109: 173-180, 2000
34. Karandikar NJ, Vanderlugt CL, Bluestone JA, Miller SD: Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease. J Neuroimmunol 89: 10-18, 1998
35. Augert A, Vindrieux D, Girard CA, Le Calvé B, Gras B, Ferrand M, Bouchet BP, Puisieux A, de Launoit Y, SimonnetH, LambeauG, Bernard D: PLA2R1 kills cancer cells by inducing mitochondrial stress. Free Radic Biol Med 65: 969-977, 2013
36. Saez NJ, Nozach H, Blemont M, Vincentelli R: High throughput quantitative expression screening and purification applied to recombinant disulfide-rich venom proteins produced in E. coli. J Vis Exp (89): e51464, 2014
37. Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, Wetzels JF, Hofstra JM, Hoxha E, Stahl RA, Lambeau G, Stöcker W, Schlumberger W: Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primarymembranous nephropathy. Clin ChimActa 421: 213-218, 2013
38. Warren SJ, Arteaga LA, Rivitti EA, Aoki V, Hans-Filho G, Qaqish BF, Lin MS, Giudice GJ, Diaz LA: The role of subclass switching in the pathogenesis of endemic pemphigus foliaceus. J InvestDermatol 120: 104-108, 2003